Niraparib With Androgen Receptor-Axis-Targeted Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer: Safety And Pharmacokinetic Results From A Phase 1b Study (BEDIVERE)

Niraparib With Androgen Receptor-Axis-Targeted Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer: Safety And Pharmacokinetic Results From A Phase 1b Study (BEDIVERE)

Fred Saad, Kim N. Chi, Neal D. Shore, Julie N. Graff, Edwin M. Posadas, Jean-Baptiste Lattouf, Byron M. Espina, Eugene Zhu, Alex Yu, Anasuya Hazra, Marc De Meulder, Rao N. V. S. Mamidi, Branislav Bradic, Peter Francis, Vinny Hayreh & Arash Rezazadeh Kalebasty

Click here to read the article.

By | April 1st, 2021|